Plus Therapeutics, Inc.
PSTV
$0.59
-$0.03-4.84%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.68% | -36.85% | 7.54% | 17.42% | -31.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.68% | -36.85% | 7.54% | 17.42% | -31.01% |
| Cost of Revenue | -55.07% | -36.45% | -21.76% | 14.64% | 95.28% |
| Gross Profit | 109.64% | 35.82% | 47.74% | -11.89% | -444.24% |
| SG&A Expenses | -23.65% | 28.29% | 31.51% | 19.97% | 14.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.16% | -7.66% | 2.73% | 17.01% | 48.80% |
| Operating Income | 58.40% | -7.18% | -1.09% | -16.86% | -148.12% |
| Income Before Tax | 275.20% | -433.61% | -2.44% | 10.72% | -98.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 275.20% | -433.61% | -2.44% | 10.72% | -98.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 275.20% | -433.61% | -2.44% | 10.72% | -98.38% |
| EBIT | 58.40% | -7.18% | -1.09% | -16.86% | -148.12% |
| EBITDA | 58.58% | -7.82% | 0.16% | -16.43% | -165.19% |
| EPS Basic | 105.44% | -3,811.41% | 41.40% | 63.35% | 23.43% |
| Normalized Basic EPS | 123.52% | -4,964.06% | 41.39% | 63.34% | 23.41% |
| EPS Diluted | 99.09% | -3,811.41% | 41.40% | 63.00% | -20.32% |
| Normalized Diluted EPS | 109.01% | -4,964.06% | 41.39% | 63.34% | 53.67% |
| Average Basic Shares Outstanding | 644.35% | -89.46% | 74.81% | 143.56% | 159.06% |
| Average Diluted Shares Outstanding | 1,846.91% | -89.46% | 74.81% | 143.56% | 328.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |